Literature DB >> 19761403

Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons.

Kelly M Podetz-Pedersen1, Jason B Bell, Terry W J Steele, Andrew Wilber, W Thomas Shier, Lalitha R Belur, R Scott McIvor, Perry B Hackett.   

Abstract

Two methods of systemic gene delivery have been extensively explored, using the mouse as a model system: hydrodynamic delivery, wherein a DNA solution equivalent in volume to 10% of the mouse weight is injected intravenously in less than 10 sec, and condensation of DNA with polyethylenimine (PEI) for standard intravenous infusion. Our goal in this study was to evaluate quantitatively the kinetics of gene expression, using these two methods for delivery of Sleeping Beauty transposons. Transposons carrying a luciferase expression cassette were injected into mice either hydrodynamically or after condensation with PEI at a PEI nitrogen-to-DNA phosphate ratio of 7. Gene expression in the lungs and liver after hydrodynamic delivery resulted in exponential decay with a half-life of about 35-40 hr between days 1 and 14 postinjection. The decay kinetics of gene expression after PEI-mediated gene delivery were more complex; an initial decay rate of 6 hr was followed by a more gradual loss of activity. Consequently, the liver became the primary site of gene expression about 4 days after injection of PEI-DNA, and by 14 days expression in the liver was 10-fold higher than in the lung. Overall levels of gene expression 2 weeks postinjection were 100- to 1000-fold lower after PEI-mediated delivery compared with hydrodynamic injection. These results provide insight into the relative effectiveness and organ specificity of these two methods of nonviral gene delivery when coupled with the Sleeping Beauty transposon system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19761403      PMCID: PMC2829452          DOI: 10.1089/hum.2009.128

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  66 in total

1.  Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer.

Authors:  D Lechardeur; K J Sohn; M Haardt; P B Joshi; M Monck; R W Graham; B Beatty; J Squire; H O'Brodovich; G L Lukacs
Journal:  Gene Ther       Date:  1999-04       Impact factor: 5.250

2.  High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA.

Authors:  G Zhang; V Budker; J A Wolff
Journal:  Hum Gene Ther       Date:  1999-07-01       Impact factor: 5.695

3.  Endothelial targeting of the Sleeping Beauty transposon within lung.

Authors:  Li Liu; Sonia Sanz; Arnold D Heggestad; Vijay Antharam; Lucia Notterpek; Bradley S Fletcher
Journal:  Mol Ther       Date:  2004-07       Impact factor: 11.454

4.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

Authors:  F Liu; Y Song; D Liu
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

5.  Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.

Authors:  Z Ivics; P B Hackett; R H Plasterk; Z Izsvák
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

6.  Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference.

Authors:  Zongyu J Chen; Betsy T Kren; Phillip Y-P Wong; Walter C Low; Clifford J Steer
Journal:  Biochem Biophys Res Commun       Date:  2005-04-08       Impact factor: 3.575

7.  Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.

Authors:  Stephanie Laufs; K Zsuzsanna Nagy; Frank A Giordano; Agnes Hotz-Wagenblatt; W Jens Zeller; Stefan Fruehauf
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

8.  PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery.

Authors:  M Ogris; S Brunner; S Schüller; R Kircheis; E Wagner
Journal:  Gene Ther       Date:  1999-04       Impact factor: 5.250

9.  Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system.

Authors:  John R Ohlfest; Paul D Lobitz; Scott G Perkinson; David A Largaespada
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

10.  Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.

Authors:  Rick S Mitchell; Brett F Beitzel; Astrid R W Schroder; Paul Shinn; Huaming Chen; Charles C Berry; Joseph R Ecker; Frederic D Bushman
Journal:  PLoS Biol       Date:  2004-08-17       Impact factor: 8.029

View more
  14 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 2.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Authors:  Perry B Hackett; Elena L Aronovich; David Hunter; Myra Urness; Jason B Bell; Steven J Kass; Laurence J N Cooper; Scott McIvor
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

Review 3.  The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

Authors:  Elena L Aronovich; R Scott McIvor; Perry B Hackett
Journal:  Hum Mol Genet       Date:  2011-04-01       Impact factor: 6.150

4.  Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters.

Authors:  Kendra A Hyland; Elena L Aronovich; Erik R Olson; Jason B Bell; Myra Urness Rusten; Roland Gunther; David W Hunter; Perry B Hackett; R Scott McIvor
Journal:  Hum Gene Ther       Date:  2017-04-19       Impact factor: 5.695

5.  Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery.

Authors:  Jason B Bell; Elena L Aronovich; Jeffrey M Schreifels; Thomas C Beadnell; Perry B Hackett
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

6.  Cellular immune response against firefly luciferase after sleeping beauty-mediated gene transfer in vivo.

Authors:  Kelly M Podetz-Pedersen; Vaiva Vezys; Nikunj V Somia; Stephen J Russell; R Scott McIvor
Journal:  Hum Gene Ther       Date:  2014-09-22       Impact factor: 5.695

Review 7.  Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.

Authors:  Zsuzsanna Izsvák; Perry B Hackett; Laurence J N Cooper; Zoltán Ivics
Journal:  Bioessays       Date:  2010-09       Impact factor: 4.345

Review 8.  Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.

Authors:  Elena L Aronovich; Perry B Hackett
Journal:  Mol Genet Metab       Date:  2014-10-07       Impact factor: 4.797

9.  Quantitative analysis of α-L-iduronidase expression in immunocompetent mice treated with the Sleeping Beauty transposon system.

Authors:  Elena L Aronovich; Bryan C Hall; Jason B Bell; R Scott McIvor; Perry B Hackett
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

10.  Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging.

Authors:  Hye-Lim Ju; Sang Hoon Ahn; Do Young Kim; Sinhwa Baek; Sook In Chung; Jinsil Seong; Kwang-Hyub Han; Simon Weonsang Ro
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.